Can any of the new obesity medications in development stand out from the pack? Which company just broke records with its IPO? And will the Food and Drug Administration allow…

Seniors' drug costs rise sharply, Enliven's leukemia drugs, and more biotech news from The Readout

Drug pricing in Europe, AI deals for VC firms, and more biotech news from The Readout

Plus a buried alcohol study gets published, and a Biosecure update.

AstraZeneca's GLP-1 pill, GSK's $10.6B cancer startup acquisition, and more biotech news from The Readout

Revolution and Tango yield promising cancer results, Incyte buys bleeding disorder drug, and more biotech news

Johnson & Johnson said it will purchase the startup Firefly Bio for $1 billion in an effort to expand its work in the suddenly buzzy field of KRAS inhibitors.

A combination of pancreatic cancer drugs from Tango Therapeutics and Revolution Medicines led to a strong response rate in an early-stage trial.

Eli Lilly presented new safety and tolerability data on retatrutide at the annual meeting of the American Diabetes Association on Saturday.

Detailed data from a midstage study offered further evidence that the obesity drug Pfizer acquired from the biotech Metsera could be dosed monthly.

RevMed's cancer drug feels out of reach for some, SCOTUS preserves key generic drug pathway, and more biotech news

The White House has used the program to reward companies that help its political goals.

Otsuka’s Voyxact slowed the loss of kidney function after one year in patients with a chronic autoimmune kidney disease, but the benefit was less than expected.

Inceptive Nucleics and Alnylam's partnership, why Grail's "failed" trial still matters, and other biotech news from The Readout

Alnylam announced a three-year deal with Inceptive, worth up to $2 billion, with $30 million up front in cash and equity in the startup.

New guidance for gene therapy developers, Lilly's deal for kidney drugs, and more biotech news from The Readout

Longevity startup NewLimit plans to launch its first clinical trial of a liver medicine after raising a staggering $435 million in new funding.

Top Pre-Revenue Biotech Acquisition Targets - June 2026

Abivax's ulcerative colitis data, Fulcrum's scrapped sickle cell drug, and more biotech news from The Readout

Abivax said its experimental treatment for ulcerative colitis showed significant efficacy in a closely watched trial, but shares of the company tanked on safety concerns.

Here is some of what you may have missed from the world's largest cancer research meeting.

Eli Lilly announces two China deals, Akeso's lung cancer bispecific payoff, and more biotech news from The Readout

The French pharma firm Servier is buying an experimental muscular dystrophy drug from Edgewise Therapeutics for $1.55 billion upfront.

ASCO Day 3: A huge advance for pancreatic cancer, a let down for Akeso and Summit, and a new approach to immunotherapy.

Low-dose, low-cost immunotherapies may help patients in poorer countries access high-tech cancer treatments.

By doing hormone therapy up front in prostate cancer cases, the hope was to shrink the relapse rate after surgery. Results were encouraging.

A lung cancer drug developed in China was a highlight of ASCO but doctors want to see follow-up in a more diverse population.

ASCO, Day 2: promising news around lung cancer, new immunotherapies, and bold words from Rick Pazdur.

Rick Pazdur on the FDA: “We've had a lot of destruction here, and it doesn't mean that we have to just go back and say, well, let's rebuild it as…

CEO Mark Goldsmith says Revolution Medicines will submit pancreatic cancer drug daraxonrasib for FDA approval soon.